The stipulation of dismissal was filed pursuant to a settlement agreement that the company entered into with Indivior and Aquestive, it add...

The pan-European STOXX 600 closed 0.8% lower at 452.84 points but rose 1.4% in June, its fifth straight month of gains.

The pan-European STOXX 600 was down 0.2 per cent, with banks, energy and mining shares falling between 0.6 per cent and 1.0 per cent.

The blue-chip FTSE 100 index climbed 0.5%, with healthcare stocks leading the gains, while the domestically focussed mid-cap index added 0....

The European retail sector was among top advancers, rising after four sessions of losses.

Indivior is in a legal battle against the launch of the copycat version of its opioid addiction treatment by competitors.

CLSA in a note said Prime Minister Narendra Modi is still a favourite to win the 2019 general election.

The scrip was 5.30 per cent down at Rs 2,565.60 at around 02.12 pm.

Buy Dr. Reddy's Laboratories Ltd. at a price target of Rs 3350.0 .

Benchmark NSE Nifty50 index was down 90.45 points at 10,565.75 while BSE Sensex was down 354.82 points at 35,119.69 around 11:30 am.

Weak results and broker notes caused some sharp moves lower.

Indivior sees a $25 million dent on its revenues due to the product of Dr Reddy's.

The Nifty Pharma was trading 2.42 per cent down at 8,943 around 11:05 am.

The court has also ordered the parties to submit a final proposed injunction order on Monday.

Dr Reddy's said in a BSE filing that the company remains confident in its legal positions on this patent.

The Nifty50 index of NSE closed at 9,974 with 40 constituents closing in the green and rest in the red.

Market stayed in the green on better auto sales and manufacturing data for the month of August.